EUVIMEDEUVIMED entdecken
Open Access

Antibody nanoparticle conjugate–based targeted immunotherapy for non–small cell lung cancer

Tanmoy Saha iD, Michaela Fojtů iD, Astha Vinay Nagar, Liya Thurakkal, Balaaji Baanupriya Srinivasan, Meghma Mukherjee iD, Astralina Sibiyon, Heena Aggarwal iD, Akash Samuel iD, Chinmayee Dash iD, Hae Lin Jang iD, Shiladitya Sengupta iD

Science Advances · 2024

DOI: 10.1126/sciadv.adi2046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Tanmoy Saha und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Nanoparticles. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of immune checkpoint inhibitors, which activate T cells, is a paradigm shift in the treatment of non–small cell lung cancer. However, the overall response remains low. To address this limitation, here we describe a novel platform, termed antibody-conjugated drug-loaded nanotherapeutics (ADN), which combines immunotherapy and molecularly targeted therapy. An ADN was designed with an anti-CD47 and anti–programmed death ligand 1 (PDL1) antibody pair on the surface of the nanoparticle and a molecularly targeted inhibitor of the PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR (mammalian target of rapamycin) pathway, PI103, entrapped in the nanoparticle. The anti–CD47-PDL1-ADN exhibited greater antitumor efficacy than current treatment options with a PDL1 inhibitor in vivo in an aggressive lung cancer immunocompetent mouse model. Dual antibody-drug–loaded nanotherapeutics can emerge as an attractive platform to improve outcomes with cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyNanoparticlesAnimalsHumansMiceCell Line, TumorB7-H1 AntigenImmunoconjugatesXenograft Model Antitumor AssaysDisease Models, AnimalCD47 AntigenImmune Checkpoint Inhibitors

Substanzen

B7-H1 AntigenImmunoconjugatesCD47 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Center for Engineered Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Orthopaedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA, USA.
  • Dana-Farber Cancer Institute, Boston, MA, USA.

ORCID-Profile: Tanmoy Saha, Michaela Fojtů, Meghma Mukherjee, Heena Aggarwal, Akash Samuel, Chinmayee Dash, Hae Lin Jang, Shiladitya Sengupta

Zitieren

APA

Saha, T., Fojtů, M., Nagar, A. V., Thurakkal, L., Srinivasan, B. B., Mukherjee, M., Sibiyon, A., Aggarwal, H., Samuel, A., Dash, C., Jang, H. L., & Sengupta, S. (2024). Antibody nanoparticle conjugate–based targeted immunotherapy for non–small cell lung cancer. Science Advances. https://doi.org/10.1126/sciadv.adi2046

Vancouver

Saha T, Fojtů M, Nagar AV, Thurakkal L, Srinivasan BB, Mukherjee M, et al. Antibody nanoparticle conjugate–based targeted immunotherapy for non–small cell lung cancer. Science Advances. 2024. doi:10.1126/sciadv.adi2046

BibTeX
@article{Saha2024,
  author = {Saha, Tanmoy and Fojtů, Michaela and Nagar, Astha Vinay and Thurakkal, Liya and Srinivasan, Balaaji Baanupriya and Mukherjee, Meghma and Sibiyon, Astralina and Aggarwal, Heena and Samuel, Akash and Dash, Chinmayee and Jang, Hae Lin and Sengupta, Shiladitya},
  title = {Antibody nanoparticle conjugate–based targeted immunotherapy for non–small cell lung cancer},
  journal = {Science Advances},
  year = {2024},
  doi = {10.1126/sciadv.adi2046}
}
Kostenlos starten →